62106-0622 NDC - HAD (ATROPINUM SULPHURICUM, BERBERIS VULGARIS, BRYONIA, CARDUUS MARIANUS, CHELIDONIUM MAJUS, ECHINACEA ANGUSTIFOLIA, LYCOPODIUM CLAVATUM, MAGNESIA PHOSPHORICA, ORYCTOLAGUS CUNICULUS (RABBIT) ADRENAL GLAND, ORYCTOLAGUS CUNICULUS (RABBIT) SPLEEN, ZINGIBER OFFICINALE (GINGER) RHIZOME)

Drug Information

Product NDC: 62106-0622

Proprietary Name: HAD

Non Proprietary Name: Atropinum sulphuricum, Berberis vulgaris, Bryonia, Carduus marianus, Chelidonium majus, Echinacea angustifolia, Lycopodium clavatum, Magnesia phosphorica, Oryctolagus cuniculus (Rabbit) Adrenal Gland, Oryctolagus cuniculus (Rabbit) Spleen, Zingiber officinale (Ginger) Rhizome

Active Ingredient(s):
  • 6 [hp_X]/30mL ATROPINE SULFATE;
  • 3 [hp_X]/30mL BERBERIS VULGARIS ROOT BARK;
  • 4 [hp_X]/30mL BRYONIA ALBA ROOT;
  • 3 [hp_X]/30mL CHELIDONIUM MAJUS ROOT;
  • 2 [hp_X]/30mL ECHINACEA, UNSPECIFIED;
  • 2 [hp_X]/30mL GINGER;
  • 12 [hp_X]/30mL LYCOPODIUM CLAVATUM SPORE;
  • 6 [hp_X]/30mL MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE;
  • 2 [hp_X]/30mL MILK THISTLE;
  • 10 [hp_X]/30mL ORYCTOLAGUS CUNICULUS ADRENAL GLAND;
  • 10 [hp_X]/30mL ORYCTOLAGUS CUNICULUS SPLEEN


Administration Route(s): ORAL

Dosage Form(s): LIQUID

Pharmacy Class(es):
  • Allergens [CS];
  • Anticholinergic [EPC];
  • Calculi Dissolution Agent [EPC];
  • Cell-mediated Immunity [PE];
  • Cholinergic Antagonists [MoA];
  • Cholinergic Muscarinic Antagonist [EPC];
  • Cholinergic Muscarinic Antagonists [MoA];
  • Dietary Proteins [CS];
  • Food Additives [CS];
  • Increased Histamine Release [PE];
  • Increased Large Intestinal Motility [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Small Intestine Fluid/Electrolyte Absorption [PE];
  • Magnesium Ion Exchange Activity [MoA];
  • Non-Standardized Food Allergenic Extract [EPC];
  • Non-Standardized Plant Allergenic Extract [EPC];
  • Osmotic Activity [MoA];
  • Osmotic Laxative [EPC];
  • Plant Proteins [CS];
  • Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]

Labeler Information

Labeler Name: Seroyal USA
Product Type: HUMAN OTC DRUG
FDA Application Number:
Marketing Category: UNAPPROVED HOMEOPATHIC
Start Marketing Date:11/25/2015

Package Information

No. Package Code Package Description Billing Unit
162106-0622-01 BOTTLE, GLASS in 1 CARTON (62106-0622-0) / 30 mL in 1 BOTTLE, GLASS

NDC Record

Field Name Field Value Definition
PRODUCT NDC62106-0622The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEHADThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAtropinum sulphuricum, Berberis vulgaris, Bryonia, Carduus marianus, Chelidonium majus, Echinacea angustifolia, Lycopodium clavatum, Magnesia phosphorica, Oryctolagus cuniculus (Rabbit) Adrenal Gland, Oryctolagus cuniculus (Rabbit) Spleen, Zingiber officinale (Ginger) RhizomeThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE11/25/2015This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEUNAPPROVED HOMEOPATHICProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMESeroyal USAName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEATROPINE SULFATE; BERBERIS VULGARIS ROOT BARK; BRYONIA ALBA ROOT; CHELIDONIUM MAJUS ROOT; ECHINACEA, UNSPECIFIED; GINGER; LYCOPODIUM CLAVATUM SPORE; MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE; MILK THISTLE; ORYCTOLAGUS CUNICULUS ADRENAL GLAND; ORYCTOLAGUS CUNICULUS SPLEENAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH6; 3; 4; 3; 2; 2; 12; 6; 2; 10; 10 
ACTIVE INGRED UNIT[hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL; [hp_X]/30mL 
PHARM CLASSESAllergens [CS], Anticholinergic [EPC], Calculi Dissolution Agent [EPC], Cell-mediated Immunity [PE], Cholinergic Antagonists [MoA], Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA], Dietary Proteins [CS], Food Additives [CS], Increased Histamine Release [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Osmotic Activity [MoA], Osmotic Laxative [EPC], Plant Proteins [CS], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023